Asia Pacific Antiviral Drugs Market size valued at over USD 7 billion in 2020 and is expected to witness -0.7% CAGR from 2021 to 2027.
Anti-viral medicines are available in the form of tablets, liquid, and powdered drugs. These drugs have ability to inhibit the reproduction of pathogenic viruses. Anti-viral drugs interfere with enzyme activity responsible for reproduction and replication of viruses causing diseases.
Get more details on this report - Request Free Sample PDF
Emergence of COVID-19 outbreak has affected millions of people in Asia Pacific, thus creating demand for anti-viral drugs for treatment. In Asia, more than 25 million cases were reported as of mid-March 2021. Increasing rate of hospitalizations associated with coronavirus infection has significantly driven the anti-viral therapeutics demand. Institutes and organizations are continuously focusing on evaluation of safety and efficacy of existing drugs as well as new therapeutics for coronavirus.
Growing burden of several infectious diseases in the region coupled with expanding pharmaceuticals market will favour the APAC anti-viral drugs industry growth. According to the World Health Organization, about 87 million people reported as chronic carriers of hepatitis B in China that accounted for approximately one third carriers of hepatitis B globally. In addition, nearly 3.8 million HIV population was reported in the South-East Asia.
The reverse transcriptase inhibitors segment dominated around 40% market share in 2020 attributed to its efficacy in treatment and management of HIV. Increasing disease prevalence in Asian countries enhances segment growth potential. These drugs are involved in competitive inhibition of reverse transcriptase leading to suppression of HIV replication. Discovery and development of non-nucleoside as well as nucleoside reverse transcriptase inhibitors positively impact the segment growth.
The HIV AIDS segment accounted for more than USD 3.2 billion revenue in 2020. According to the World Health Organization, in 2018, there were about 1.25 million people living with HIV infection in China. Disease prevalence is higher in other emerging economies including South Korea, that will stimulate product demand. Moreover, increasing awareness regarding available treatment therapies will contribute to the segment revenue growth.
The branded anti-viral drugs segment is projected to reach USD 5 billion by 2027. High drug effectivity with ownership of brand by the firms will favor the segment demand. Increasing product launches for severe infectious diseases by leading pharmaceutical giants with extensive R&D will offer unprecedented growth opportunities to the segment. For instance, the launch of Biktarvy by Gilead accelerated the HIV products revenue growth by 12% in 2018 compared to 2017.
The pediatric segment revenue was over USD 1.5 billion in 2020. Pediatric population is highly prone to infections due to undeveloped immunity. Higher risk of hospital-acquired infections drives the product demand. Increasing prevalence of HIV infection in children will influence the market expansion.
India antiviral drugs market size is anticipated to cross USD 1.2 billion by 2027 owing to improving access to healthcare facilities with government support. For instance, The National AIDS Control Programme (NACP) by the government is aimed towards prevention and control of HIV/AIDS in India. In April 2017, the Minister of Health and Family Welfare announced a new test-and-treat policy committed towards providing access to HIV treatment for overall population with HIV in the country. Moreover, the companies are launching new products to cater to escalating burden of COVID-19. Recently, Abbott announced the launch of Favipiravir for emergency use in India for the treatment of mild to moderate COVID-19.
Few of the major industry players include AbbVie Inc., Gilead Sciences, Merck & Co., Bristol-Myers Squibb, GlaxoSmithKline, and Aurobindo Pharma Ltd. among several others. These companies are continuously innovating their product and are involved in collaborations to cater growing patient pool. For instance, in February 2020, Gilead Sciences announced partnership with Chinese health authorities for assessment of its anti-viral drug candidate Remdesivir for treatment of novel coronavirus.